



Figure S1 Tumor types and immunotherapy options in patients with ICI myocarditis. ICI, immune checkpoint inhibitor.

Table S1 Cox regression analysis of characteristics related to the overall survival of ICI myocarditis

Characteristics	40-days overall survival		1-year overall survival	
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age	1.013 (0.974, 1.054)	0.52	1.006 (0.977, 1.036)	0.69
BMI	0.950 (0.940, 4.162)	0.39	0.926 (0.846, 1.015)	0.10
Male	1.065 (0.442, 2.569)	0.89	0.999 (0.508, 1.967)	>0.99
Smoking	0.690 (0.295, 1.613)	0.39	1.161 (0.623, 2.166)	0.64
Drinking	0.158 (0.021, 1.168)	0.07	0.725 (0.321, 1.641)	0.44
CAD	0.585 (0.138, 2.490)	0.47	0.820 (0.321, 2.096)	0.68
Hypertension	0.989 (0.392, 2.492)	0.98	1.045 (0.522, 2.094)	0.90
Diabetes	0.919 (0.274, 3.083)	0.89	0.798 (0.312, 2.042)	0.64
Tumor type		0.87		0.77
Lung cancer	0.658 (0.221, 1.958)	0.45	1.246 (0.509, 3.051)	0.63
Esophageal carcinoma	0.539 (0.171, 1.700)	0.29	0.791 (0.297, 2.110)	0.64
Gastric cancer	0.687 (0.201, 2.349)	0.55	1.455 (0.561, 3.776)	0.44
liver cancer	0.709 (0.147, 3.414)	0.67	1.042 (0.276, 3.935)	0.95
Tumor stage	1.355 (0.606, 3.029)	0.46	1.476 (0.791, 2.755)	0.22
Combined chemotherapy	0.655 (0.224, 1.918)	0.44	0.485 (0.223, 1.056)	0.07
Combined targeted-therapy	1.597 (0.633, 4.027)	0.32	1.376 (0.654, 2.893)	0.40
Combined radiotherapy	0.740 (0.276, 1.983)	0.55	0.794 (0.378, 1.668)	0.54
Type of ICIs	1.314 (0.392, 4.407)	0.66	1.264 (0.495, 3.228)	0.62
Concomitant irAEs	1.619 (0.719, 3.645)	0.25	1.187 (0.639, 2.207)	0.59
LVEF at myocarditis onset	0.932 (0.900, 0.964)	<0.001	0.944 (0.917, 0.972)	<0.001
Steroid dosage [†]	1.178 (0.659, 2.106)	0.58	0.876 (0.558, 1.375)	0.57
Other treatments for ICI myocarditis	0.721 (0.215, 2.419)	0.60	0.377 (0.116, 1.223)	0.10

[†], in our study population, oral or intravenous steroid therapy ≤ 80 mg/day is regarded as the low-dose group, while any higher dose or high-dose pulse treatment is regarded as the high-dose group. BMI, body mass index; CAD, Coronary heart disease; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; LVEF, left ventricular ejection fraction.